Physicians' Academy for Cardiovascular Education
With early initiation of atorvastatin 80 mg plus ezetimibe 10 mg, and escalation with bempedoic acid or PCSK9i if needed, all 85 patients hospitalized for STEMI achieved the 2019 ESC/EAS Guidelines LDL-c target.
The optimal duration of dual antiplatelet therapy after percutaneous coronary intervention is an extensive topic of debate in patients at high bleeding risk. This systematic review and meta-analysis provides more clarity.
Prof. Maciej Banach and colleagues have written a guidance paper on individualized therapy in patients with statin intolerance. Prof. Banach presents the steps on how to effectively diagnose and treat statin intolerance.
The SGLT2 inhibitor empagliflozin reduces the risk of cardiovascular death or first hospitalization for HF in patients with HF and an LVEF >40%, compared with placebo. It is unclear whether this effect is modified by SBP.
In a longitudinal, population-based cohort study, a polygenic risk score for coronary artery disease (CAD) had greatest predictive power in participants aged <50 years. Additionally, several individuals were reclassified, which affected their eligibility for statin therapy.
This pooled analysis of the DAPA-HF and DELIVER trials showed a 14% lower risk of CV death with dapagliflozin versus placebo regardless of LVEF, mainly due to lower, albeit nonsignificant, rates of sudden death and HF death.
When a risk stratification tool was used to decide in the ED whether patients with acute HF were discharged or admitted, the risk of all-cause mortality or hospitalization for CV causes was reduced compared with usual care.
Patients with polyvascular disease (PVD) have a very high cardiovascular risk and require intensive lipid-lowering therapy. This post-hoc analysis (ORION-9, ORION-10 and ORION-11) examined the efficacy and safety of inclisiran in patients with and without PVD.
A prespecified analysis of the DELIVER trial showed early (<2 weeks) and sustained (>2 years) reductions in CV death or worsening HF with dapagliflozin compared with placebo in patients with HFmrEF or HFpEF.
The ROSE2 trial with obecitrapib in combination with ezetimbe as an adjunct to high-intensity statin met its primary endpoint of LDL-c reduction.
A Taiwanese observational study evaluated CV and renal outcomes in statin-treated patients with stage 3 CKD across different LDL‐c levels.
A label update for the GLP-1RA semaglutide has been approved by the FDA, which allows use of semaglutide as a first-line option for adults with T2DM.
